Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (abre una nueva ventana)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Fuente‎: Cancer 2013;119(21):3784-7.

Indexado en‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (abre una nueva ventana)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (abre una nueva ventana)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Fuente‎: Lancet 1989;334(8655):122-4.

Indexado en‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (abre una nueva ventana)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (abre una nueva ventana)

Ben-Bassat I, Douer D, Ramot B.

Fuente‎: Eur J Haematol 1990;45(2):86-9.

Indexado en‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (abre una nueva ventana)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (abre una nueva ventana)

Dean A, Tuffin P.

Fuente‎: J Pain Symptom Manage 1997;13(1):20-4.

Indexado en‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (abre una nueva ventana)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (abre una nueva ventana)

Ford PA, Grant SJ, Mick R, Keck G.

Fuente‎: J Clin Oncol 2015;33(15):1674-9.

Indexado en‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (abre una nueva ventana)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (abre una nueva ventana)

Garewal HS, Durie BG.

Fuente‎: Scand J Haematol 1985;35(5):497-500.

Indexado en‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (abre una nueva ventana)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (abre una nueva ventana)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Fuente‎: Cancer 2006;107(1):136-40.

Indexado en‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (abre una nueva ventana)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (abre una nueva ventana)

Marshall A, Li A, Drucker A, Dzik W.

Fuente‎: Hematol Oncol 2016;34(3):147-53.

Indexado en‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (abre una nueva ventana)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (abre una nueva ventana)

Prokopchuk-Gauk O, Brose K.

Fuente‎: Cureus 2015;7(12):e428.

Indexado en‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (abre una nueva ventana)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (abre una nueva ventana)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Fuente‎: Leuk Lymphoma 1995;19(1-2):141-4.

Indexado en‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (abre una nueva ventana)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (abre una nueva ventana)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Fuente‎: Hematol Oncol 2008;26(4):241-6.

Indexado en‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (abre una nueva ventana)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (abre una nueva ventana)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Fuente‎: Am J Hematol 2006;81(9):720.

Indexado en‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (abre una nueva ventana)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (abre una nueva ventana)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Fuente‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Indexado en‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (abre una nueva ventana)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (abre una nueva ventana)

Erduran E, Bahadir A, Mutlu M.

Fuente‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Indexado en‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (abre una nueva ventana)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (abre una nueva ventana)

Franchini M, Veneri D, Lippi G.

Fuente‎: Bone Marrow Transplant 2007;39(12):729-35.

Indexado en‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (abre una nueva ventana)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (abre una nueva ventana)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Fuente‎: Am J Hematol 2002;69(3):219-22.

Indexado en‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (abre una nueva ventana)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (abre una nueva ventana)

Hsieh A, Cheong I.

Fuente‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Indexado en‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (abre una nueva ventana)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (abre una nueva ventana)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Fuente‎: Haemostasis 1996;26 Suppl 1:159-64.

Indexado en‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (abre una nueva ventana)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (abre una nueva ventana)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Fuente‎: Med Oncol 2010;27(1):16-9.

Indexado en‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (abre una nueva ventana)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (abre una nueva ventana)

Vidarsson B, Önundarson PT.

Fuente‎: Thromb Haemost 2000;83(4):634-5.

Indexado en‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (abre una nueva ventana)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (abre una nueva ventana)

Zver S, Andoljšek D, Černelč P.

Fuente‎: Eur J Haematol 2004;72(6):455-6.

Indexado en‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (abre una nueva ventana)

Management of bleeding complications of hematologic malignancies. (abre una nueva ventana)

Green D.

Fuente‎: Semin Thromb Hemost 2007;33(4):427-34.

Indexado en‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (abre una nueva ventana)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (abre una nueva ventana)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Fuente‎: Int J Lab Hematol 2013;35(4):457-9.

Indexado en‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (abre una nueva ventana)

Management of bleeding in patients with advanced cancer. (abre una nueva ventana)

Pereira J, Phan T.

Fuente‎: Oncologist 2004;9(5):561-70.

Indexado en‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (abre una nueva ventana)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (abre una nueva ventana)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Fuente‎: Haematologica 1997;82(5):584-7.

Indexado en‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (abre una nueva ventana)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (abre una nueva ventana)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Fuente‎: Bull Cancer 2006;93(2):E7-12.

Indexado en‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (abre una nueva ventana)